

**TDMS No.** 99024 - 08  
**Test Type:** CHRONIC  
**Route:** GAVAGE  
**Species/Strain:** MICE/B6C3F1

**P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS**

Androstenedione  
**CAS Number:** 63-05-8

**Date Report Requested:** 05/09/2008  
**Time Report Requested:** 12:55:58  
**First Dose M/F:** 12/16/02 / 12/16/02  
**Lab:** SRI

F1\_M3

**C Number:** C99024C  
**Lock Date:** 06/29/2006  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** ALL  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL  
**Study Gender:** Both  
**TDMSE Version:** 2.0.0

TDMS No. 99024 - 08  
Test Type: CHRONIC  
Route: GAVAGE  
Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
Androstenedione  
CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
Time Report Requested: 12:55:58  
First Dose M/F: 12/16/02 / 12/16/02  
Lab: SRI

## HISTORICAL CONTROL STUDIES From October 2007 Report

### SAME ROUTE

91005-08 -- Methylene blue trihydrate (GAVAGE METHYLCELLULOSE)

### ALL ROUTES

88138-04 -- Benzophenone (ORAL FEED)  
99027-04 -- Chromium picolinate monohydrate (ORAL FEED)  
05174-06 -- Cresols (ORAL FEED)  
96011-06 -- Cumene (INHALATION AIR)  
97003-08 -- 1,2-Dibromo-2,4-dicyanobutane (SKIN ETHANOL)  
93020-08 -- Diisopropylcarbodiimide (SKIN ETHANOL)  
88004-06 -- Divinylbenzene (INHALATION AIR)  
88123-07 -- Formamide (GAVAGE WATER)  
95011-06 -- 5-(Hydroxymethyl)-2-furfural (GAVAGE WATER)  
88105-04 -- Isoeugenol (GAVAGE CORN OIL)  
97006-02 -- Methyl isobutyl ketone (INHALATION AIR)  
91005-08 -- Methylene blue trihydrate (GAVAGE METHYLCELLULOSE)  
92012-06 -- 2-Methylimidazole (ORAL FEED)  
92013-06 -- 4-Methylimidazole (ORAL FEED)  
88006-04 -- alpha-Methylstyrene (INHALATION AIR)  
99023-04 -- beta-Myrcene (GAVAGE CORN OIL)  
97008-06 -- Propargyl alcohol (INHALATION AIR)  
20114-06 -- Sodium dichromate dihydrate (VI) (ORAL WATER)  
96001-06 -- Stoddard solvent (type IIC) (INHALATION AIR)  
05109-14 -- Triethanolamine (SKIN ACETONE)  
96019-06 -- Water disinfection byproducts (Bromochloroacetic acid) (ORAL WATER)  
96018-04 -- Water disinfection byproducts (Bromodichloromethane) (ORAL WATER)  
96017-06 -- Water disinfection byproducts (Dibromoacetic acid) (ORAL WATER)  
96015-06 -- Water disinfection byproducts (Dibromoacetonitrile) (ORAL WATER)

**TDMS No.** 99024 - 08  
**Test Type:** CHRONIC  
**Route:** GAVAGE  
**Species/Strain:** MICE/B6C3F1

**P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS**  
Androstenedione  
**CAS Number:** 63-05-8

**Date Report Requested:** 05/09/2008  
**Time Report Requested:** 12:55:58  
**First Dose M/F:** 12/16/02 / 12/16/02  
**Lab:** SRI

**HISTORICAL CONTROL STUDIES**  
**From October 2007 Report**

96010-04 -- Water disinfection byproducts (Sodium chlorate) (ORAL WATER)

**TDMS No.** 99024 - 08  
**Test Type:** CHRONIC  
**Route:** GAVAGE  
**Species/Strain:** MICE/B6C3F1

**P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS**  
Androstenedione  
**CAS Number:** 63-05-8

**Date Report Requested:** 05/09/2008  
**Time Report Requested:** 12:55:58  
**First Dose M/F:** 12/16/02 / 12/16/02  
**Lab:** SRI

**FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED.  
IN OTHER TISSUES/ORGANS RATES ARE BASED ON THE NUMBER OF ANIMALS NECROPSIED.**

Adrenal Cortex  
Adrenal Medulla  
Bone Marrow  
Gallbladder  
Islets, Pancreatic  
Kidney  
Liver  
Lung  
Ovary  
Pancreas  
Pituitary Gland  
Spleen  
Testes  
Thyroid Gland  
Urinary Bladder

TDMS No. 99024 - 08  
Test Type: CHRONIC  
Route: GAVAGE  
Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
Androstenedione  
CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
Time Report Requested: 12:55:58  
First Dose M/F: 12/16/02 / 12/16/02  
Lab: SRI

## SUMMARY OF STATISTICALLY SIGNIFICANT ( $P \leq .05$ ) RESULTS IN THE ANALYSIS OF Androstenedione

### MALE MICE

#### Organ

Intestine Small: Site Unspecified  
Liver

Lung  
Spleen  
All Organs

### FEMALE MICE

#### Organ

Islets, Pancreatic  
Liver

Lung

Skin

Thyroid Gland: Follicular Cell  
All Organs

#### Morphology

Carcinoma  
Hepatocellular Adenoma  
Hepatocellular Carcinoma or Hepatoblastoma  
Hepatocellular Carcinoma or Hepatocellular Adenoma  
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma  
Alveolar/Bronchiolar Carcinoma  
Hemangiosarcoma  
Benign Tumors  
Malignant and Benign Tumors

#### Morphology

Adenoma  
Hepatocellular Adenoma  
Hepatocellular Carcinoma  
Hepatocellular Carcinoma or Hepatoblastoma  
Hepatocellular Carcinoma or Hepatocellular Adenoma  
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma  
Alveolar/Bronchiolar Adenoma  
Alveolar/Bronchiolar Carcinoma  
Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, or Fibrous Histiocytoma  
Fibrosarcoma  
Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma  
Carcinoma or Adenoma  
Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or Undifferentiated Cell Type  
Malignant Tumors

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Adrenal Cortex  
 Adenoma**

**TUMOR RATES**

OVERALL (a)	1/50 (2%)	5/49 (10%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/43.3	5/47.36	1/44.32	1/45.17
POLY-3 PERCENT (g)	2.3%	10.6%	2.3%	2.2%
TERMINAL (d)	1/36 (3%)	5/43 (12%)	1/34 (3%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	729 (T)
HC TUMORS SAME RTE	5/48 (10%)			
HC TUMORS ALL RTES	74/1142 (7%)			

**STATISTICAL TESTS**

POLY 3	P=0.289N	P=0.124	P=0.756N	P=0.751N
POLY 1.5	P=0.297N	P=0.113	P=0.759N	P=0.755N
POLY 6	P=0.279N	P=0.138	P=0.752N	P=0.746N
COCH-ARM / FISHERS	P=0.312N	P=0.098	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.264N	P=0.066	P=0.493N	P=0.487N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
<b>Harderian Gland Adenoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	7/50 (14%)	9/50 (18%)	7/50 (14%)	4/50 (8%)
POLY-3 RATE (b)	7/43.99	9/48.39	7/44.79	4/45.24
POLY-3 PERCENT (g)	15.9%	18.6%	15.6%	8.8%
TERMINAL (d)	6/36 (17%)	8/44 (18%)	5/34 (15%)	3/37 (8%)
FIRST INCIDENCE	489	721	660	712
HC TUMORS SAME RTE	8/50 (16%)			
HC TUMORS ALL RTEs	152/1149 (13%)			

**STATISTICAL TESTS**

POLY 3	P=0.145N	P=0.474	P=0.600N	P=0.244N
POLY 1.5	P=0.146N	P=0.441	P=0.611N	P=0.252N
POLY 6	P=0.143N	P=0.514	P=0.584N	P=0.234N
COCH-ARM / FISHERS	P=0.147N	P=0.393	P=0.613N	P=0.262N
MAX-ISO-POLY-3	P=0.219N	P=0.372	P=0.485N	P=0.159N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTEs	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
<b>Harderian Gland Carcinoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	3/50 (6%)
POLY-3 RATE (b)	2/43.3	0/48.36	0/44.32	3/45.97
POLY-3 PERCENT (g)	4.6%	0%	0%	6.5%
TERMINAL (d)	2/36 (6%)	0/44 (0%)	0/34 (0%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	---	---	513
HC TUMORS SAME RTE	3/50 (6%)			
HC TUMORS ALL RTES	30/1149 (3%)			

**STATISTICAL TESTS**

POLY 3	P=0.188	P=0.214N	P=0.232N	P=0.527
POLY 1.5	P=0.192	P=0.223N	P=0.235N	P=0.516
POLY 6	P=0.184	P=0.203N	P=0.228N	P=0.541
COCH-ARM / FISHERS	P=0.198	P=0.247N	P=0.247N	P=0.500
MAX-ISO-POLY-3	P=0.125	P=0.076N	P=0.076N	P=0.352
HISTCONT SAME RTE	P=0.199	(e)	(e)	P=0.510
HISTCONT ALL RTES	P=0.143	(e)	(e)	P=0.218



TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Harderian Gland  
 Carcinoma or Adenoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	9/50 (18%)	9/50 (18%)	7/50 (14%)	7/50 (14%)
POLY-3 RATE (b)	9/43.99	9/48.39	7/44.79	7/46.04
POLY-3 PERCENT (g)	20.5%	18.6%	15.6%	15.2%
TERMINAL (d)	8/36 (22%)	8/44 (18%)	5/34 (15%)	4/37 (11%)
FIRST INCIDENCE	489	721	660	513
HC TUMORS SAME RTE	11/50 (22%)			
HC TUMORS ALL RTES	176/1149 (15%)			

**STATISTICAL TESTS**

POLY 3	P=0.311N	P=0.515N	P=0.376N	P=0.354N
POLY 1.5	P=0.316N	P=0.551N	P=0.389N	P=0.370N
POLY 6	P=0.305N	P=0.472N	P=0.358N	P=0.332N
COCH-ARM / FISHERS	P=0.321N	P=0.602N	P=0.393N	P=0.393N
MAX-ISO-POLY-3	P=0.424N	P=0.413N	P=0.280N	P=0.263N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
<b>Intestine Small: Jejunum Carcinoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	1/50 (2%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	1/43.3	0/48.36	2/44.32	1/45.17
POLY-3 PERCENT (g)	2.3%	0%	4.5%	2.2%
TERMINAL (d)	1/36 (3%)	0/44 (0%)	2/34 (6%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	---	729 (T)	729 (T)
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	14/1149 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.547	P=0.478N	P=0.508	P=0.751N
POLY 1.5	P=0.550	P=0.487N	P=0.503	P=0.755N
POLY 6	P=0.543	P=0.468N	P=0.515	P=0.746N
COCH-ARM / FISHERS	P=0.554	P=0.500N	P=0.500	P=0.753N
MAX-ISO-POLY-3	P=0.392	P=0.158N	P=0.290	P=0.487N
HISTCONT SAME RTE	P=0.274	(e)	P=0.135	P=0.218
HISTCONT ALL RTES	P=0.438	(e)	P=0.168	P=0.475

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Intestine Small: Site Unspecified  
 Carcinoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	3/50 (6%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	3/43.3	0/48.36	2/44.32	1/45.17
POLY-3 PERCENT (g)	6.9%	0%	4.5%	2.2%
TERMINAL (d)	3/36 (8%)	0/44 (0%)	2/34 (6%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	---	729 (T)	729 (T)
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	18/1149 (2%)			

**STATISTICAL TESTS**

POLY 3	P=0.388N	P=0.100N	P=0.489N	P=0.290N
POLY 1.5	P=0.380N	P=0.107N	P=0.496N	P=0.296N
POLY 6	P=0.397N	P=0.093N	P=0.481N	P=0.282N
COCH-ARM / FISHERS	P=0.370N	P=0.121N	P=0.500N	P=0.309N
MAX-ISO-POLY-3	P=0.181N	P=0.038N*	P=0.316N	P=0.148N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

---

**Islets, Pancreatic  
 Adenoma**

**TUMOR RATES**

OVERALL (a)	2/50 (4%)	2/50 (4%)	2/50 (4%)	5/49 (10%)
POLY-3 RATE (b)	2/43.3	2/48.36	2/44.7	5/45.02
POLY-3 PERCENT (g)	4.6%	4.1%	4.5%	11.1%
TERMINAL (d)	2/36 (6%)	2/44 (5%)	1/34 (3%)	4/37 (11%)
FIRST INCIDENCE	729 (T)	729 (T)	620	493
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	11/1136 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.104	P=0.653N	P=0.683N	P=0.232
POLY 1.5	P=0.103	P=0.670N	P=0.689N	P=0.222
POLY 6	P=0.105	P=0.634N	P=0.674N	P=0.244
COCH-ARM / FISHERS	P=0.101	P=0.691N	P=0.691N	P=0.210
MAX-ISO-POLY-3	P=0.160	P=0.457N	P=0.486N	P=0.135
HISTCONT SAME RTE	P=0.070	P=0.240	P=0.212	P=0.136
HISTCONT ALL RTES	P<0.001**	P=0.112	P=0.107	P=0.003**

---

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
<b>Liver Hemangiosarcoma</b>				
<b>TUMOR RATES</b>				
OVERALL (a)	3/50 (6%)	1/50 (2%)	5/50 (10%)	3/50 (6%)
POLY-3 RATE (b)	3/43.71	1/48.36	5/44.33	3/45.32
POLY-3 PERCENT (g)	6.9%	2.1%	11.3%	6.6%
TERMINAL (d)	2/36 (6%)	1/44 (2%)	4/34 (12%)	2/37 (5%)
FIRST INCIDENCE	610	729 (T)	725	690
HC TUMORS SAME RTE	2/50 (4%)			
HC TUMORS ALL RTES	30/1146 (3%)			

**STATISTICAL TESTS**

POLY 3	P=0.459	P=0.270N	P=0.364	P=0.646N
POLY 1.5	P=0.463	P=0.284N	P=0.358	P=0.652N
POLY 6	P=0.455	P=0.255N	P=0.370	P=0.637N
COCH-ARM / FISHERS	P=0.468	P=0.309N	P=0.357	P=0.661N
MAX-ISO-POLY-3	P=0.322	P=0.142N	P=0.239	P=0.481N
HISTCONT SAME RTE	P=0.306	P=1.000	P=0.142	P=0.237
HISTCONT ALL RTES	P=0.093	P=1.000	P=0.039*	P=0.219

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver  
 Hepatoblastoma

**TUMOR RATES**

OVERALL (a)	3/50 (6%)	8/50 (16%)	7/50 (14%)	8/50 (16%)
POLY-3 RATE (b)	3/43.3	8/48.82	7/44.67	8/45.49
POLY-3 PERCENT (g)	6.9%	16.4%	15.7%	17.6%
TERMINAL (d)	3/36 (8%)	7/44 (16%)	6/34 (18%)	6/37 (16%)
FIRST INCIDENCE	729 (T)	593	631	648
HC TUMORS SAME RTE	2/50 (4%)			
HC TUMORS ALL RTES	43/1146 (4%)			

**STATISTICAL TESTS**

POLY 3	P=0.182	P=0.141	P=0.169	P=0.114
POLY 1.5	P=0.177	P=0.123	P=0.162	P=0.107
POLY 6	P=0.188	P=0.165	P=0.179	P=0.123
COCH-ARM / FISHERS	P=0.170	P=0.100	P=0.159	P=0.100
MAX-ISO-POLY-3	P=0.132	P=0.094	P=0.101	P=0.067
HISTCONT SAME RTE	P=0.184	P=0.158	P=0.159	P=0.116
HISTCONT ALL RTES	P=0.026*	P=0.107	P=0.117	P=0.075

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
<b>Liver</b>				
<b>Hepatocellular Adenoma</b>				
<b>TUMOR RATES</b>				
OVERALL (a)	32/50 (64%)	38/50 (76%)	29/50 (58%)	43/50 (86%)
POLY-3 RATE (b)	32/44.97	38/48.36	29/45.37	43/46.84
POLY-3 PERCENT (g)	71.2%	78.6%	63.9%	91.8%
TERMINAL (d)	27/36 (75%)	38/44 (86%)	25/34 (74%)	36/37 (97%)
FIRST INCIDENCE	597	729 (T)	613	554
HC TUMORS SAME RTE	28/50 (56%)			
HC TUMORS ALL RTES	544/1146 (48%)			

**STATISTICAL TESTS**

POLY 3	P=0.009**	P=0.270	P=0.298N	P=0.005**
POLY 1.5	P=0.010**	P=0.211	P=0.327N	P=0.006**
POLY 6	P=0.008**	P=0.335	P=0.269N	P=0.005**
COCH-ARM / FISHERS	P=0.017*	P=0.138	P=0.341N	P=0.010**
MAX-ISO-POLY-3	P=0.011*	P=0.203	P=0.224N	P=0.002**
HISTCONT SAME RTE	P=0.019*	P=0.128	P=0.543	P=0.005**
HISTCONT ALL RTES	P=0.006**	P=0.108	P=0.337	P=0.003**

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

---

**Liver  
 Hepatocellular Carcinoma**

**TUMOR RATES**

OVERALL (a)	26/50 (52%)	33/50 (66%)	28/50 (56%)	32/50 (64%)
POLY-3 RATE (b)	26/48.15	33/49.97	28/47.66	32/48.66
POLY-3 PERCENT (g)	54%	66%	58.7%	65.8%
TERMINAL (d)	16/36 (44%)	28/44 (64%)	16/34 (47%)	22/37 (60%)
FIRST INCIDENCE	398	593	472	485
HC TUMORS SAME RTE	13/50 (26%)			
HC TUMORS ALL RTES	317/1146 (28%)			

**STATISTICAL TESTS**

POLY 3	P=0.225	P=0.155	P=0.397	P=0.163
POLY 1.5	P=0.227	P=0.135	P=0.391	P=0.159
POLY 6	P=0.228	P=0.181	P=0.415	P=0.172
COCH-ARM / FISHERS	P=0.232	P=0.111	P=0.421	P=0.156
MAX-ISO-POLY-3	P=0.189	P=0.115	P=0.320	P=0.118
HISTCONT SAME RTE	P=0.104	P=0.129	P=0.157	P=0.125
HISTCONT ALL RTES	P<0.001**	P=0.013*	P=0.035*	P=0.015*

---



TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Liver  
 Hepatocellular Carcinoma or Hepatoblastoma**

**TUMOR RATES**

OVERALL (a)	27/50 (54%)	35/50 (70%)	30/50 (60%)	36/50 (72%)
POLY-3 RATE (b)	27/48.15	35/49.97	30/48.02	36/48.66
POLY-3 PERCENT (g)	56.1%	70.1%	62.5%	74%
TERMINAL (d)	17/36 (47%)	30/44 (68%)	17/34 (50%)	26/37 (70%)
FIRST INCIDENCE	398	593	472	485
HC TUMORS SAME RTE	15/50 (30%)			
HC TUMORS ALL RTES	346/1146 (30%)			

**STATISTICAL TESTS**

POLY 3	P=0.077	P=0.108	P=0.333	P=0.047*
POLY 1.5	P=0.078	P=0.093	P=0.320	P=0.046*
POLY 6	P=0.077	P=0.130	P=0.362	P=0.051
COCH-ARM / FISHERS	P=0.084	P=0.074	P=0.343	P=0.048*
MAX-ISO-POLY-3	P=0.049*	P=0.078	P=0.262	P=0.030*
HISTCONT SAME RTE	P=0.083	P=0.124	P=0.148	P=0.053
HISTCONT ALL RTES	P<0.001**	P=0.017*	P=0.043*	P=0.013*

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Liver  
 Hepatocellular Carcinoma or Hepatocellular Adenoma**

**TUMOR RATES**

OVERALL (a)	41/50 (82%)	47/50 (94%)	42/50 (84%)	48/50 (96%)
POLY-3 RATE (b)	41/48.15	47/49.97	42/47.78	48/48.72
POLY-3 PERCENT (g)	85.2%	94.1%	87.9%	98.5%
TERMINAL (d)	31/36 (86%)	42/44 (96%)	29/34 (85%)	37/37 (100%)
FIRST INCIDENCE	398	593	472	485
HC TUMORS SAME RTE	37/50 (74%)			
HC TUMORS ALL RTEs	729/1146 (64%)			

**STATISTICAL TESTS**

POLY 3	P=0.025*	P=0.122	P=0.460	P=0.012*
POLY 1.5	P=0.030*	P=0.090	P=0.441	P=0.015*
POLY 6	P=0.024*	P=0.176	P=0.517	P=0.012*
COCH-ARM / FISHERS	P=0.051	P=0.061	P=0.500	P=0.026*
MAX-ISO-POLY-3	P=0.010**	P=0.068	P=0.341	P=0.004**
HISTCONT SAME RTE	P=0.018*	P=0.118	P=0.138	P=0.007**
HISTCONT ALL RTEs	P=0.009**	P=0.077	P=0.176	P=0.004**

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

Liver  
 Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma

**TUMOR RATES**

OVERALL (a)	41/50 (82%)	47/50 (94%)	43/50 (86%)	48/50 (96%)
POLY-3 RATE (b)	41/48.15	47/49.97	43/48.13	48/48.72
POLY-3 PERCENT (g)	85.2%	94.1%	89.4%	98.5%
TERMINAL (d)	31/36 (86%)	42/44 (96%)	29/34 (85%)	37/37 (100%)
FIRST INCIDENCE	398	593	472	485
HC TUMORS SAME RTE	38/50 (76%)			
HC TUMORS ALL RTES	740/1146 (65%)			

**STATISTICAL TESTS**

POLY 3	P=0.024*	P=0.122	P=0.374	P=0.012*
POLY 1.5	P=0.028*	P=0.090	P=0.342	P=0.015*
POLY 6	P=0.023*	P=0.176	P=0.454	P=0.012*
COCH-ARM / FISHERS	P=0.048*	P=0.061	P=0.393	P=0.026*
MAX-ISO-POLY-3	P=0.009**	P=0.068	P=0.263	P=0.004**
HISTCONT SAME RTE	P=0.017*	P=0.118	P=0.124	P=0.007**
HISTCONT ALL RTES	P=0.010**	P=0.077	P=0.175	P=0.004**

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lung  
 Alveolar/Bronchiolar Adenoma**

**TUMOR RATES**

OVERALL (a)	7/50 (14%)	7/50 (14%)	7/50 (14%)	5/50 (10%)
POLY-3 RATE (b)	7/43.3	7/48.64	7/44.4	5/46.28
POLY-3 PERCENT (g)	16.2%	14.4%	15.8%	10.8%
TERMINAL (d)	7/36 (19%)	6/44 (14%)	6/34 (18%)	2/37 (5%)
FIRST INCIDENCE	729 (T)	652	708	526
HC TUMORS SAME RTE	11/50 (22%)			
HC TUMORS ALL RTES	209/1148 (18%)			

**STATISTICAL TESTS**

POLY 3	P=0.287N	P=0.521N	P=0.594N	P=0.333N
POLY 1.5	P=0.296N	P=0.559N	P=0.607N	P=0.352N
POLY 6	P=0.278N	P=0.477N	P=0.579N	P=0.308N
COCH-ARM / FISHERS	P=0.307N	P=0.613N	P=0.613N	P=0.380N
MAX-ISO-POLY-3	P=0.395N	P=0.410N	P=0.479N	P=0.237N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lung  
 Alveolar/Bronchiolar Carcinoma**

**TUMOR RATES**

OVERALL (a)	11/50 (22%)	9/50 (18%)	4/50 (8%)	13/50 (26%)
POLY-3 RATE (b)	11/44.56	9/48.82	4/44.4	13/45.4
POLY-3 PERCENT (g)	24.7%	18.4%	9%	28.6%
TERMINAL (d)	7/36 (19%)	7/44 (16%)	3/34 (9%)	11/37 (30%)
FIRST INCIDENCE	581	606	708	688
HC TUMORS SAME RTE	1/50 (2%)			
HC TUMORS ALL RTES	115/1148 (10%)			

**STATISTICAL TESTS**

POLY 3	P=0.244	P=0.316N	P=0.043N*	P=0.427
POLY 1.5	P=0.252	P=0.348N	P=0.044N*	P=0.420
POLY 6	P=0.234	P=0.283N	P=0.042N*	P=0.432
COCH-ARM / FISHERS	P=0.263	P=0.402N	P=0.045N*	P=0.408
MAX-ISO-POLY-3	P=0.150	P=0.242N	P=0.023N*	P=0.337
HISTCONT SAME RTE	P=0.119	P=0.297	P=0.525	P=0.155
HISTCONT ALL RTES	P=0.015*	P=0.212	P=1.000	P=0.036*

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Lung  
 Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma**

**TUMOR RATES**

OVERALL (a)	16/50 (32%)	15/50 (30%)	10/50 (20%)	17/50 (34%)
POLY-3 RATE (b)	16/44.56	15/49.1	10/44.4	17/46.5
POLY-3 PERCENT (g)	35.9%	30.6%	22.5%	36.6%
TERMINAL (d)	12/36 (33%)	12/44 (27%)	9/34 (27%)	12/37 (32%)
FIRST INCIDENCE	581	606	708	526
HC TUMORS SAME RTE	12/50 (24%)			
HC TUMORS ALL RTES	309/1148 (27%)			

**STATISTICAL TESTS**

POLY 3	P=0.422	P=0.371N	P=0.122N	P=0.561
POLY 1.5	P=0.421	P=0.421N	P=0.126N	P=0.537
POLY 6	P=0.424	P=0.319N	P=0.119N	P=0.585N
COCH-ARM / FISHERS	P=0.418	P=0.500N	P=0.127N	P=0.500
MAX-ISO-POLY-3	P=0.397	P=0.300N	P=0.081N	P=0.474
HISTCONT SAME RTE	P=0.324	P=0.465	P=1.000	P=0.191
HISTCONT ALL RTES	P=0.363	P=0.537	P=1.000	P=0.246

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

---

**Mammary Gland  
 Carcinoma**

**TUMOR RATES**

	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.3	0/48.36	0/44.32	0/45.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	1/1149 (0%)			

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

---

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Mammary Gland  
 Carcinoma or Adenoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.3	0/48.36	0/44.32	0/45.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	1/1149 (0%)			

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)



TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

---

**Mammary Gland  
 Fibroma, Fibroadenoma, Carcinoma, or Adenoma**

---

TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.3	0/48.36	0/44.32	0/45.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	1/1149 (0%)			

**STATISTICAL TESTS**

---

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

---

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Pituitary Gland: Pars Distalis or Unspecified Site  
 Adenoma**

**TUMOR RATES**

OVERALL (a)	0/50 (0%)	0/49 (0%)	0/49 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.3	0/47.36	0/43.33	0/45.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/43 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	3/1119 (0%)			

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
<b>Skeletal Muscle Sarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.76	0/48.36	0/44.32	0/45.17
POLY-3 PERCENT (g)	2.3%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	590	---	---	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	0/1149 (0%)			

**STATISTICAL TESTS**

POLY 3	P=0.408N	P=0.480N	P=0.497N	P=0.494N
POLY 1.5	P=0.403N	P=0.488N	P=0.500N	P=0.496N
POLY 6	P=0.415N	P=0.471N	P=0.495N	P=0.491N
COCH-ARM / FISHERS	P=0.394N	P=0.500N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.124N	P=0.158N	P=0.158N	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Skin  
 Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, or Fibrous Histiocytoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	1/50 (2%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	1/43.63	1/48.36	3/45.66	0/45.17
POLY-3 PERCENT (g)	2.3%	2.1%	6.6%	0%
TERMINAL (d)	0/36 (0%)	1/44 (2%)	1/34 (3%)	0/37 (0%)
FIRST INCIDENCE	636	729 (T)	256	---
HC TUMORS SAME RTE	1/50 (2%)			
HC TUMORS ALL RTES	14/1149 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.359N	P=0.737N	P=0.322	P=0.493N
POLY 1.5	P=0.358N	P=0.746N	P=0.315	P=0.496N
POLY 6	P=0.360N	P=0.726N	P=0.329	P=0.490N
COCH-ARM / FISHERS	P=0.358N	P=0.753N	P=0.309	P=0.500N
MAX-ISO-POLY-3	P=0.249N	P=0.471N	P=0.171	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
<b>Skin</b>				
<b>Fibrosarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.3	0/48.36	1/44.32	0/45.17
POLY-3 PERCENT (g)	0%	0%	2.3%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	1/34 (3%)	0/37 (0%)
FIRST INCIDENCE	---	---	729 (T)	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	0/1149 (0%)			

**STATISTICAL TESTS**

POLY 3	P=0.790N	(e)	P=0.505	(e)
POLY 1.5	P=0.789N	(e)	P=0.502	(e)
POLY 6	P=0.790N	(e)	P=0.508	(e)
COCH-ARM / FISHERS	P=0.789	(e)	P=0.500	(e)
MAX-ISO-POLY-3	P=0.399	(e)	P=0.164	(e)
HISTCONT SAME RTE	(h)	(e)	(h)	(e)
HISTCONT ALL RTES	(h)	(e)	(h)	(e)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

---

**Skin  
 Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma**

---

TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	0/50 (0%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	1/43.63	0/48.36	3/45.66	0/45.17
POLY-3 PERCENT (g)	2.3%	0%	6.6%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	1/34 (3%)	0/37 (0%)
FIRST INCIDENCE	636	---	256	---
HC TUMORS SAME RTE	1/50 (2%)			
HC TUMORS ALL RTES	11/1149 (1%)			

**STATISTICAL TESTS**

---

POLY 3	P=0.454N	P=0.480N	P=0.322	P=0.493N
POLY 1.5	P=0.451N	P=0.488N	P=0.315	P=0.496N
POLY 6	P=0.459N	P=0.471N	P=0.329	P=0.490N
COCH-ARM / FISHERS	P=0.446N	P=0.500N	P=0.309	P=0.500N
MAX-ISO-POLY-3	P=0.292N	P=0.158N	P=0.171	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

---

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
<b>Skin</b>				
<b>Hemangiosarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/43.3	2/48.36	1/44.43	0/45.17
POLY-3 PERCENT (g)	2.3%	4.1%	2.3%	0%
TERMINAL (d)	1/36 (3%)	2/44 (5%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	701	---
HC TUMORS SAME RTE	1/50 (2%)			
HC TUMORS ALL RTES	7/1149 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.243N	P=0.538	P=0.755N	P=0.492N
POLY 1.5	P=0.246N	P=0.523	P=0.758N	P=0.495N
POLY 6	P=0.240N	P=0.556	P=0.750N	P=0.487N
COCH-ARM / FISHERS	P=0.250N	P=0.500	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.252N	P=0.322	P=0.492N	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
<b>Skin</b>				
<b>Liposarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.3	0/48.36	0/44.32	0/45.17
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	0/1149 (0%)			

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)



TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Spleen  
 Hemangiosarcoma**

**TUMOR RATES**

OVERALL (a)	1/50 (2%)	1/50 (2%)	5/50 (10%)	1/50 (2%)
POLY-3 RATE (b)	1/43.3	1/48.36	5/44.61	1/45.17
POLY-3 PERCENT (g)	2.3%	2.1%	11.2%	2.2%
TERMINAL (d)	1/36 (3%)	1/44 (2%)	3/34 (9%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	729 (T)	683	729 (T)
HC TUMORS SAME RTE	2/49 (4%)			
HC TUMORS ALL RTES	21/1136 (2%)			

**STATISTICAL TESTS**

POLY 3	P=0.614N	P=0.735N	P=0.108	P=0.751N
POLY 1.5	P=0.614N	P=0.746N	P=0.104	P=0.755N
POLY 6	P=0.614N	P=0.723N	P=0.113	P=0.746N
COCH-ARM / FISHERS	P=0.614	P=0.753N	P=0.102	P=0.753N
MAX-ISO-POLY-3	P=0.254	P=0.469N	P=0.050*	P=0.487N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Stomach, Forestomach  
 Squamous Cell Carcinoma or Papilloma Squamous**

TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	2/43.95	0/48.36	2/44.67	1/45.17
POLY-3 PERCENT (g)	4.6%	0%	4.5%	2.2%
TERMINAL (d)	1/36 (3%)	0/44 (0%)	1/34 (3%)	1/37 (3%)
FIRST INCIDENCE	513	---	631	729 (T)
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	13/1149 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.563N	P=0.217N	P=0.688N	P=0.490N
POLY 1.5	P=0.557N	P=0.225N	P=0.693N	P=0.494N
POLY 6	P=0.570N	P=0.207N	P=0.682N	P=0.485N
COCH-ARM / FISHERS	P=0.548N	P=0.247N	P=0.691N	P=0.500N
MAX-ISO-POLY-3	P=0.406N	P=0.076N	P=0.493N	P=0.275N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Stomach, Forestomach  
 Squamous Cell Papilloma**

TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	0/50 (0%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	2/43.95	0/48.36	1/44.32	1/45.17
POLY-3 PERCENT (g)	4.6%	0%	2.3%	2.2%
TERMINAL (d)	1/36 (3%)	0/44 (0%)	1/34 (3%)	1/37 (3%)
FIRST INCIDENCE	513	---	729 (T)	729 (T)
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	11/1149 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.569N	P=0.217N	P=0.497N	P=0.490N
POLY 1.5	P=0.563N	P=0.225N	P=0.500N	P=0.494N
POLY 6	P=0.577N	P=0.207N	P=0.493N	P=0.485N
COCH-ARM / FISHERS	P=0.554N	P=0.247N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.267N	P=0.076N	P=0.279N	P=0.275N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**Thyroid Gland: Follicular Cell  
 Carcinoma or Adenoma**

**TUMOR RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.3	0/48.36	1/44.32	0/45.17
POLY-3 PERCENT (g)	0%	0%	2.3%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	1/34 (3%)	0/37 (0%)
FIRST INCIDENCE	---	---	729 (T)	---
HC TUMORS SAME RTE	3/50 (6%)			
HC TUMORS ALL RTES	22/1142 (2%)			

**STATISTICAL TESTS**

POLY 3	P=0.790N	(e)	P=0.505	(e)
POLY 1.5	P=0.789N	(e)	P=0.502	(e)
POLY 6	P=0.790N	(e)	P=0.508	(e)
COCH-ARM / FISHERS	P=0.789	(e)	P=0.500	(e)
MAX-ISO-POLY-3	P=0.399	(e)	P=0.164	(e)
HISTCONT SAME RTE	(h)	(e)	(h)	(e)
HISTCONT ALL RTES	(h)	(e)	(h)	(e)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
<b>All Organs</b>				
<b>Hemangioma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/43.3	0/48.36	1/44.32	1/45.17
POLY-3 PERCENT (g)	2.3%	0%	2.3%	2.2%
TERMINAL (d)	1/36 (3%)	0/44 (0%)	1/34 (3%)	1/37 (3%)
FIRST INCIDENCE	729 (T)	---	729 (T)	729 (T)
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	9/1149 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.553	P=0.478N	P=0.756N	P=0.751N
POLY 1.5	P=0.557	P=0.487N	P=0.759N	P=0.755N
POLY 6	P=0.549	P=0.468N	P=0.752N	P=0.746N
COCH-ARM / FISHERS	P=0.562	P=0.500N	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.542	P=0.158N	P=0.493N	P=0.487N
HISTCONT SAME RTE	P=0.278	(e)	P=0.212	P=0.218
HISTCONT ALL RTES	P=0.408	(e)	P=0.277	P=0.280

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**All Organs  
 Hemangiosarcoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	5/50 (10%)	4/50 (8%)	8/50 (16%)	5/50 (10%)
POLY-3 RATE (b)	5/43.71	4/48.36	8/44.62	5/45.32
POLY-3 PERCENT (g)	11.4%	8.3%	17.9%	11%
TERMINAL (d)	4/36 (11%)	4/44 (9%)	5/34 (15%)	4/37 (11%)
FIRST INCIDENCE	610	729 (T)	683	690
HC TUMORS SAME RTE	6/50 (12%)			
HC TUMORS ALL RTES	67/1149 (6%)			

**STATISTICAL TESTS**

POLY 3	P=0.520	P=0.437N	P=0.288	P=0.608N
POLY 1.5	P=0.522	P=0.462N	P=0.279	P=0.617N
POLY 6	P=0.519	P=0.410N	P=0.299	P=0.596N
COCH-ARM / FISHERS	P=0.524	P=0.500N	P=0.277	P=0.630N
MAX-ISO-POLY-3	P=0.412	P=0.315N	P=0.198	P=0.475N
HISTCONT SAME RTE	P=0.537	P=1.000	P=0.311	P=1.000
HISTCONT ALL RTES	P=0.100	P=0.465	P=0.050*	P=0.275

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**All Organs  
 Hemangiosarcoma or Hemangioma**

TUMOR RATES	#	#	#	#
OVERALL (a)	5/50 (10%)	4/50 (8%)	9/50 (18%)	6/50 (12%)
POLY-3 RATE (b)	5/43.71	4/48.36	9/44.62	6/45.32
POLY-3 PERCENT (g)	11.4%	8.3%	20.2%	13.2%
TERMINAL (d)	4/36 (11%)	4/44 (9%)	6/34 (18%)	5/37 (14%)
FIRST INCIDENCE	610	729 (T)	683	690
HC TUMORS SAME RTE	6/50 (12%)			
HC TUMORS ALL RTES	76/1149 (7%)			

**STATISTICAL TESTS**

POLY 3	P=0.381	P=0.437N	P=0.202	P=0.525
POLY 1.5	P=0.383	P=0.462N	P=0.195	P=0.515
POLY 6	P=0.378	P=0.410N	P=0.212	P=0.538
COCH-ARM / FISHERS	P=0.386	P=0.500N	P=0.194	P=0.500
MAX-ISO-POLY-3	P=0.282	P=0.315N	P=0.133	P=0.398
HISTCONT SAME RTE	P=0.409	P=1.000	P=0.218	P=0.564
HISTCONT ALL RTES	P=0.046*	P=0.531	P=0.028*	P=0.180

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

---

**All Organs  
 Histiocytic Sarcoma**

---

TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.3	0/48.36	1/44.33	0/45.17
POLY-3 PERCENT (g)	0%	0%	2.3%	0%
TERMINAL (d)	0/36 (0%)	0/44 (0%)	0/34 (0%)	0/37 (0%)
FIRST INCIDENCE	---	---	725	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	7/1149 (1%)			

**STATISTICAL TESTS**

---

POLY 3	P=0.790N	(e)	P=0.505	(e)
POLY 1.5	P=0.789N	(e)	P=0.502	(e)
POLY 6	P=0.790N	(e)	P=0.508	(e)
COCH-ARM / FISHERS	P=0.789	(e)	P=0.500	(e)
MAX-ISO-POLY-3	P=0.399	(e)	P=0.164	(e)
HISTCONT SAME RTE	(h)	(e)	(h)	(e)
HISTCONT ALL RTES	(h)	(e)	(h)	(e)

---



TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

---

**All Organs  
 Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or Undifferentiated Cell Type**

---

TUMOR RATES	#	#	#	#
OVERALL (a)	4/50 (8%)	6/50 (12%)	3/50 (6%)	6/50 (12%)
POLY-3 RATE (b)	4/43.48	6/48.36	3/44.32	6/46.52
POLY-3 PERCENT (g)	9.2%	12.4%	6.8%	12.9%
TERMINAL (d)	3/36 (8%)	6/44 (14%)	3/34 (9%)	1/37 (3%)
FIRST INCIDENCE	682	729 (T)	729 (T)	526
HC TUMORS SAME RTE	2/50 (4%)			
HC TUMORS ALL RTES	34/1149 (3%)			

**STATISTICAL TESTS**

---

POLY 3	P=0.399	P=0.438	P=0.490N	P=0.413
POLY 1.5	P=0.389	P=0.411	P=0.497N	P=0.395
POLY 6	P=0.414	P=0.469	P=0.482N	P=0.437
COCH-ARM / FISHERS	P=0.374	P=0.370	P=0.500N	P=0.370
MAX-ISO-POLY-3	P=0.468	P=0.321	P=0.339N	P=0.296
HISTCONT SAME RTE	P=0.144	P=0.151	P=0.424	P=0.143
HISTCONT ALL RTES	P<0.001**	P=0.011*	P=0.192	P=0.011*

---

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
<b>All Organs</b>				
<b>Benign Tumors</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	38/50 (76%)	43/50 (86%)	35/50 (70%)	46/50 (92%)
POLY-3 RATE (b)	38/46.32	43/48.67	35/46.1	46/48.48
POLY-3 PERCENT (g)	82%	88.3%	75.9%	94.9%
TERMINAL (d)	31/36 (86%)	41/44 (93%)	28/34 (82%)	36/37 (97%)
FIRST INCIDENCE	489	652	613	493
HC TUMORS SAME RTE	37/50 (74%)			
HC TUMORS ALL RTES	753/1149 (66%)			

**STATISTICAL TESTS**

POLY 3	P=0.048*	P=0.269	P=0.312N	P=0.034*
POLY 1.5	P=0.043*	P=0.216	P=0.337N	P=0.028*
POLY 6	P=0.062	P=0.335	P=0.270N	P=0.051
COCH-ARM / FISHERS	P=0.046*	P=0.154	P=0.326N	P=0.027*
MAX-ISO-POLY-3	P=0.047*	P=0.183	P=0.225N	P=0.016*
HISTCONT SAME RTE	P=0.081	P=0.134	P=1.000	P=0.030*
HISTCONT ALL RTES	P=0.018*	P=0.137	P=0.427	P=0.017*

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
<b>All Organs</b>				
<b>Malignant Tumors</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	37/50 (74%)	41/50 (82%)	38/50 (76%)	44/50 (88%)
POLY-3 RATE (b)	37/48.79	41/50	38/49.08	44/50
POLY-3 PERCENT (g)	75.8%	82%	77.4%	88%
TERMINAL (d)	25/36 (69%)	35/44 (80%)	23/34 (68%)	31/37 (84%)
FIRST INCIDENCE	398	593	256	485
HC TUMORS SAME RTE	26/50 (52%)			
HC TUMORS ALL RTES	582/1149 (51%)			

**STATISTICAL TESTS**

POLY 3	P=0.095	P=0.306	P=0.521	P=0.092
POLY 1.5	P=0.084	P=0.277	P=0.502	P=0.078
POLY 6	P=0.108	P=0.340	P=0.551	P=0.109
COCH-ARM / FISHERS	P=0.072	P=0.235	P=0.500	P=0.062
MAX-ISO-POLY-3	P=0.100	P=0.229	P=0.425	P=0.057
HISTCONT SAME RTE	P=0.074	P=0.148	P=0.181	P=0.099
HISTCONT ALL RTES	P<0.001**	P=0.033*	P=0.060	P=0.018*

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG

**All Organs  
 Malignant and Benign Tumors**

TUMOR RATES	#	#	#	#
OVERALL (a)	47/50 (94%)	50/50 (100%)	44/50 (88%)	50/50 (100%)
POLY-3 RATE (b)	47/49.44	50/50	44/49.08	50/50
POLY-3 PERCENT (g)	95.1%	100%	89.6%	100%
TERMINAL (d)	34/36 (94%)	44/44 (100%)	29/34 (85%)	37/37 (100%)
FIRST INCIDENCE	398	593	256	485
HC TUMORS SAME RTE	46/50 (92%)			
HC TUMORS ALL RTES	976/1149 (85%)			

**STATISTICAL TESTS**

POLY 3	P=0.240	P=0.159	P=0.260N	P=0.159
POLY 1.5	P=0.218	P=0.138	P=0.266N	P=0.138
POLY 6	P=0.269	P=0.194	P=0.239N	P=0.194
COCH-ARM / FISHERS	P=0.206	P=0.121	P=0.243N	P=0.121
MAX-ISO-POLY-3	P=0.136	P=0.047*	P=0.153N	P=0.047*
HISTCONT SAME RTE	P=0.215	P=0.082	P=1.000	P=0.082
HISTCONT ALL RTES	P=0.063	P=0.051	P=0.468	P=0.051

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Adrenal Cortex  
 Adenoma**

**TUMOR RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.96	0/45.74	0/44.97	0/45.74
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	5/1244 (0%)			

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
<b>Harderian Gland Adenoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	9/50 (18%)	5/50 (10%)	11/50 (22%)	4/50 (8%)
POLY-3 RATE (b)	9/44.34	5/45.74	11/46.27	4/45.74
POLY-3 PERCENT (g)	20.3%	10.9%	23.8%	8.8%
TERMINAL (d)	8/35 (23%)	5/40 (13%)	9/40 (23%)	4/40 (10%)
FIRST INCIDENCE	622	729 (T)	508	729 (T)
HC TUMORS SAME RTE	4/50 (8%)			
HC TUMORS ALL RTEs	128/1249 (10%)			

**STATISTICAL TESTS**

POLY 3	P=0.129N	P=0.174N	P=0.442	P=0.103N
POLY 1.5	P=0.135N	P=0.180N	P=0.424	P=0.109N
POLY 6	P=0.121N	P=0.167N	P=0.465	P=0.094N
COCH-ARM / FISHERS	P=0.139N	P=0.194N	P=0.402	P=0.117N
MAX-ISO-POLY-3	P=0.115N	P=0.113N	P=0.348	P=0.061N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTEs	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
<b>Harderian Gland Carcinoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	1/50 (2%)	1/50 (2%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	1/44.49	1/45.74	1/44.97	2/45.78
POLY-3 PERCENT (g)	2.3%	2.2%	2.2%	4.4%
TERMINAL (d)	0/35 (0%)	1/40 (3%)	1/40 (3%)	1/40 (3%)
FIRST INCIDENCE	565	729 (T)	729 (T)	718
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	33/1249 (3%)			

**STATISTICAL TESTS**

POLY 3	P=0.380	P=0.754N	P=0.758N	P=0.510
POLY 1.5	P=0.376	P=0.756N	P=0.760N	P=0.505
POLY 6	P=0.386	P=0.752N	P=0.756N	P=0.518
COCH-ARM / FISHERS	P=0.373	P=0.753N	P=0.753N	P=0.500
MAX-ISO-POLY-3	P=0.439	P=0.491N	P=0.496N	P=0.292
HISTCONT SAME RTE	P=0.068	P=0.216	P=0.210	P=0.138
HISTCONT ALL RTES	P=0.513	P=1.000	P=1.000	P=0.364

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Harderian Gland  
 Carcinoma or Adenoma**

**TUMOR RATES**

	#	#	#	#
OVERALL (a)	10/50 (20%)	6/50 (12%)	12/50 (24%)	6/50 (12%)
POLY-3 RATE (b)	10/44.87	6/45.74	12/46.27	6/45.78
POLY-3 PERCENT (g)	22.3%	13.1%	25.9%	13.1%
TERMINAL (d)	8/35 (23%)	6/40 (15%)	10/40 (25%)	5/40 (13%)
FIRST INCIDENCE	565	729 (T)	508	718
HC TUMORS SAME RTE	4/50 (8%)			
HC TUMORS ALL RTES	160/1249 (13%)			

**STATISTICAL TESTS**

POLY 3	P=0.234N	P=0.192N	P=0.436	P=0.192N
POLY 1.5	P=0.241N	P=0.196N	P=0.422	P=0.199N
POLY 6	P=0.223N	P=0.187N	P=0.452	P=0.181N
COCH-ARM / FISHERS	P=0.243N	P=0.207N	P=0.405	P=0.207N
MAX-ISO-POLY-3	P=0.220N	P=0.128N	P=0.344	P=0.128N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)



TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Intestine Small: Jejunum  
 Carcinoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.96	0/45.74	0/44.97	0/45.74
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	4/1249 (0%)			

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Intestine Small: Site Unspecified  
 Carcinoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.96	0/45.74	0/44.97	0/45.74
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	1/50 (2%)			
HC TUMORS ALL RTES	6/1249 (1%)			

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Islets, Pancreatic  
 Adenoma**

**TUMOR RATES**

OVERALL (a)	0/49 (0%)	2/50 (4%)	4/49 (8%)	4/48 (8%)
POLY-3 RATE (b)	0/43.53	2/45.74	4/44.63	4/44.84
POLY-3 PERCENT (g)	0%	4.4%	9%	8.9%
TERMINAL (d)	0/35 (0%)	2/40 (5%)	4/40 (10%)	3/40 (8%)
FIRST INCIDENCE	---	729 (T)	729 (T)	654
HC TUMORS SAME RTE	1/46 (2%)			
HC TUMORS ALL RTES	12/1228 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.137	P=0.248	P=0.063	P=0.064
POLY 1.5	P=0.130	P=0.246	P=0.062	P=0.061
POLY 6	P=0.147	P=0.251	P=0.065	P=0.068
COCH-ARM / FISHERS	P=0.125	P=0.253	P=0.059	P=0.056
MAX-ISO-POLY-3	P=0.060	P=0.086	P=0.022*	P=0.023*
HISTCONT SAME RTE	P=0.099	P=0.145	P=0.039*	P=0.041*
HISTCONT ALL RTES	P=0.002**	P=0.088	P=0.004**	P=0.004**

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Liver  
 Hemangiosarcoma

**TUMOR RATES**

OVERALL (a)	0/50 (0%)	1/50 (2%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	0/43.96	1/46.12	1/44.97	1/46.55
POLY-3 PERCENT (g)	0%	2.2%	2.2%	2.2%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	1/40 (3%)	0/40 (0%)
FIRST INCIDENCE	---	622	729 (T)	420
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	11/1245 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.567	P=0.510	P=0.505	P=0.511
POLY 1.5	P=0.560	P=0.506	P=0.502	P=0.506
POLY 6	P=0.576	P=0.514	P=0.508	P=0.518
COCH-ARM / FISHERS	P=0.551	P=0.500	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.355	P=0.171	P=0.164	P=0.173
HISTCONT SAME RTE	P=0.281	P=0.213	P=0.207	P=0.215
HISTCONT ALL RTES	P=0.411	P=0.203	P=0.195	P=0.206

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
<b>Liver</b>				
<b>Hepatoblastoma</b>				
<b>TUMOR RATES</b>				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.96	0/45.74	0/44.97	0/45.74
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	6/1245 (1%)			
<b>STATISTICAL TESTS</b>				
POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Liver  
 Hepatocellular Adenoma**

**TUMOR RATES**

OVERALL (a)	14/50 (28%)	16/50 (32%)	18/50 (36%)	28/50 (56%)
POLY-3 RATE (b)	14/44.34	16/46.27	18/46.08	28/45.82
POLY-3 PERCENT (g)	31.6%	34.6%	39.1%	61.1%
TERMINAL (d)	13/35 (37%)	14/40 (35%)	16/40 (40%)	27/40 (68%)
FIRST INCIDENCE	622	622	520	708
HC TUMORS SAME RTE	15/50 (30%)			
HC TUMORS ALL RTEs	345/1245 (28%)			

**STATISTICAL TESTS**

POLY 3	P<0.001**	P=0.468	P=0.299	P=0.003**
POLY 1.5	P<0.001**	P=0.449	P=0.280	P=0.003**
POLY 6	P<0.001**	P=0.497	P=0.326	P=0.004**
COCH-ARM / FISHERS	P<0.001**	P=0.414	P=0.260	P=0.004**
MAX-ISO-POLY-3	P=0.002**	P=0.382	P=0.232	P=0.002**
HISTCONT SAME RTE	P=0.003**	P=0.362	P=0.252	P=0.004**
HISTCONT ALL RTEs	P=0.002**	P=0.483	P=0.283	P=0.002**

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
<b>Liver</b>				
<b>Hepatocellular Carcinoma</b>				
<b>TUMOR RATES</b>				
OVERALL (a)	5/50 (10%)	13/50 (26%)	15/50 (30%)	15/50 (30%)
POLY-3 RATE (b)	5/44.13	13/46.06	15/46.91	15/45.87
POLY-3 PERCENT (g)	11.3%	28.2%	32%	32.7%
TERMINAL (d)	3/35 (9%)	11/40 (28%)	11/40 (28%)	13/40 (33%)
FIRST INCIDENCE	687	685	442	708
HC TUMORS SAME RTE	5/50 (10%)			
HC TUMORS ALL RTES	131/1245 (11%)			

**STATISTICAL TESTS**

POLY 3	P=0.098	P=0.038*	P=0.015*	P=0.012*
POLY 1.5	P=0.093	P=0.036*	P=0.013*	P=0.011*
POLY 6	P=0.108	P=0.042*	P=0.018*	P=0.014*
COCH-ARM / FISHERS	P=0.093	P=0.033*	P=0.011*	P=0.011*
MAX-ISO-POLY-3	P=0.019*	P=0.023*	P=0.009**	P=0.007**
HISTCONT SAME RTE	P=0.033*	P=0.042*	P=0.017*	P=0.013*
HISTCONT ALL RTES	P=0.015*	P=0.024*	P=0.009**	P=0.007**

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Liver  
 Hepatocellular Carcinoma or Hepatoblastoma**

**TUMOR RATES**

OVERALL (a)	5/50 (10%)	13/50 (26%)	15/50 (30%)	15/50 (30%)
POLY-3 RATE (b)	5/44.13	13/46.06	15/46.91	15/45.87
POLY-3 PERCENT (g)	11.3%	28.2%	32%	32.7%
TERMINAL (d)	3/35 (9%)	11/40 (28%)	11/40 (28%)	13/40 (33%)
FIRST INCIDENCE	687	685	442	708
HC TUMORS SAME RTE	5/50 (10%)			
HC TUMORS ALL RTES	136/1245 (11%)			

**STATISTICAL TESTS**

POLY 3	P=0.098	P=0.038*	P=0.015*	P=0.012*
POLY 1.5	P=0.093	P=0.036*	P=0.013*	P=0.011*
POLY 6	P=0.108	P=0.042*	P=0.018*	P=0.014*
COCH-ARM / FISHERS	P=0.093	P=0.033*	P=0.011*	P=0.011*
MAX-ISO-POLY-3	P=0.019*	P=0.023*	P=0.009**	P=0.007**
HISTCONT SAME RTE	P=0.033*	P=0.042*	P=0.017*	P=0.013*
HISTCONT ALL RTES	P=0.018*	P=0.024*	P=0.009**	P=0.007**



TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Liver  
 Hepatocellular Carcinoma or Hepatocellular Adenoma**

**TUMOR RATES**

OVERALL (a)	17/50 (34%)	23/50 (46%)	27/50 (54%)	32/50 (64%)
POLY-3 RATE (b)	17/44.51	23/46.44	27/47.39	32/45.87
POLY-3 PERCENT (g)	38.2%	49.5%	57%	69.8%
TERMINAL (d)	14/35 (40%)	20/40 (50%)	22/40 (55%)	30/40 (75%)
FIRST INCIDENCE	622	622	442	708
HC TUMORS SAME RTE	19/50 (38%)			
HC TUMORS ALL RTEs	419/1245 (34%)			

**STATISTICAL TESTS**

POLY 3	P=0.004**	P=0.188	P=0.052	P<0.001**
POLY 1.5	P=0.004**	P=0.175	P=0.042*	P<0.001**
POLY 6	P=0.004**	P=0.209	P=0.067	P=0.002**
COCH-ARM / FISHERS	P=0.006**	P=0.154	P=0.035*	P=0.002**
MAX-ISO-POLY-3	P=0.002**	P=0.141	P=0.037*	P<0.001**
HISTCONT SAME RTE	P=0.004**	P=0.229	P=0.066	P=0.002**
HISTCONT ALL RTEs	P=0.002**	P=0.165	P=0.039*	P<0.001**

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

Liver  
 Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma

**TUMOR RATES**

OVERALL (a)	17/50 (34%)	23/50 (46%)	27/50 (54%)	32/50 (64%)
POLY-3 RATE (b)	17/44.51	23/46.44	27/47.39	32/45.87
POLY-3 PERCENT (g)	38.2%	49.5%	57%	69.8%
TERMINAL (d)	14/35 (40%)	20/40 (50%)	22/40 (55%)	30/40 (75%)
FIRST INCIDENCE	622	622	442	708
HC TUMORS SAME RTE	19/50 (38%)			
HC TUMORS ALL RTES	421/1245 (34%)			

**STATISTICAL TESTS**

POLY 3	P=0.004**	P=0.188	P=0.052	P<0.001**
POLY 1.5	P=0.004**	P=0.175	P=0.042*	P<0.001**
POLY 6	P=0.004**	P=0.209	P=0.067	P=0.002**
COCH-ARM / FISHERS	P=0.006**	P=0.154	P=0.035*	P=0.002**
MAX-ISO-POLY-3	P=0.002**	P=0.141	P=0.037*	P<0.001**
HISTCONT SAME RTE	P=0.004**	P=0.229	P=0.066	P=0.002**
HISTCONT ALL RTES	P=0.002**	P=0.165	P=0.039*	P<0.001**

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Lung  
 Alveolar/Bronchiolar Adenoma**

**TUMOR RATES**

OVERALL (a)	0/50 (0%)	2/50 (4%)	3/50 (6%)	0/50 (0%)
POLY-3 RATE (b)	0/43.96	2/45.74	3/44.97	0/45.74
POLY-3 PERCENT (g)	0%	4.4%	6.7%	0%
TERMINAL (d)	0/35 (0%)	2/40 (5%)	3/40 (8%)	0/40 (0%)
FIRST INCIDENCE	---	729 (T)	729 (T)	---
HC TUMORS SAME RTE	1/50 (2%)			
HC TUMORS ALL RTES	65/1248 (5%)			

**STATISTICAL TESTS**

POLY 3	P=0.286N	P=0.246	P=0.123	(e)
POLY 1.5	P=0.293N	P=0.243	P=0.121	(e)
POLY 6	P=0.276N	P=0.250	P=0.126	(e)
COCH-ARM / FISHERS	P=0.300N	P=0.247	P=0.121	(e)
MAX-ISO-POLY-3	P=0.242N	P=0.085	P=0.041*	(e)
HISTCONT SAME RTE	(h)	(h)	(h)	(e)
HISTCONT ALL RTES	(h)	(h)	(h)	(e)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Lung  
 Alveolar/Bronchiolar Carcinoma**

**TUMOR RATES**

OVERALL (a)	4/50 (8%)	3/50 (6%)	0/50 (0%)	5/50 (10%)
POLY-3 RATE (b)	4/44.13	3/46.41	0/44.97	5/46.48
POLY-3 PERCENT (g)	9.1%	6.5%	0%	10.8%
TERMINAL (d)	3/35 (9%)	2/40 (5%)	0/40 (0%)	4/40 (10%)
FIRST INCIDENCE	684	502	---	463
HC TUMORS SAME RTE	5/50 (10%)			
HC TUMORS ALL RTES	47/1248 (4%)			

**STATISTICAL TESTS**

POLY 3	P=0.240	P=0.473N	P=0.058N	P=0.532
POLY 1.5	P=0.235	P=0.482N	P=0.059N	P=0.518
POLY 6	P=0.246	P=0.461N	P=0.056N	P=0.550
COCH-ARM / FISHERS	P=0.231	P=0.500N	P=0.059N	P=0.500
MAX-ISO-POLY-3	P=0.244	P=0.327N	P=0.019N*	P=0.395
HISTCONT SAME RTE	P=0.358	P=1.000	(e)	P=0.560
HISTCONT ALL RTES	P=0.187	P=0.410	(e)	P=0.126

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Lung  
 Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma**

**TUMOR RATES**

OVERALL (a)	4/50 (8%)	5/50 (10%)	3/50 (6%)	5/50 (10%)
POLY-3 RATE (b)	4/44.13	5/46.41	3/44.97	5/46.48
POLY-3 PERCENT (g)	9.1%	10.8%	6.7%	10.8%
TERMINAL (d)	3/35 (9%)	4/40 (10%)	3/40 (8%)	4/40 (10%)
FIRST INCIDENCE	684	502	729 (T)	463
HC TUMORS SAME RTE	6/50 (12%)			
HC TUMORS ALL RTES	107/1248 (9%)			

**STATISTICAL TESTS**

POLY 3	P=0.490	P=0.531	P=0.490N	P=0.532
POLY 1.5	P=0.479	P=0.521	P=0.495N	P=0.518
POLY 6	P=0.503	P=0.544	P=0.482N	P=0.550
COCH-ARM / FISHERS	P=0.468	P=0.500	P=0.500N	P=0.500
MAX-ISO-POLY-3	P=0.599	P=0.394	P=0.339N	P=0.395
HISTCONT SAME RTE	P=0.745	P=0.560	P=1.000	P=0.560
HISTCONT ALL RTES	P=0.705	P=0.501	P=1.000	P=0.502

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
<b>Mammary Gland Carcinoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.96	2/45.74	0/44.97	0/45.74
POLY-3 PERCENT (g)	2.3%	4.4%	0%	0%
TERMINAL (d)	1/35 (3%)	2/40 (5%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	---	---
HC TUMORS SAME RTE	2/50 (4%)			
HC TUMORS ALL RTES	16/1249 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.253N	P=0.514	P=0.495N	P=0.492N
POLY 1.5	P=0.256N	P=0.509	P=0.498N	P=0.496N
POLY 6	P=0.250N	P=0.520	P=0.492N	P=0.487N
COCH-ARM / FISHERS	P=0.259N	P=0.500	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.187N	P=0.296	P=0.158N	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
<b>Mammary Gland Carcinoma or Adenoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	1/50 (2%)	3/50 (6%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.96	3/45.92	0/44.97	0/45.74
POLY-3 PERCENT (g)	2.3%	6.5%	0%	0%
TERMINAL (d)	1/35 (3%)	2/40 (5%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	729 (T)	681	---	---
HC TUMORS SAME RTE	2/50 (4%)			
HC TUMORS ALL RTES	16/1249 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.176N	P=0.321	P=0.495N	P=0.492N
POLY 1.5	P=0.179N	P=0.316	P=0.498N	P=0.496N
POLY 6	P=0.172N	P=0.329	P=0.492N	P=0.487N
COCH-ARM / FISHERS	P=0.185N	P=0.309	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.132N	P=0.171	P=0.158N	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Mammary Gland  
 Fibroma, Fibroadenoma, Carcinoma, or Adenoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	3/50 (6%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/43.96	3/45.92	0/44.97	0/45.74
POLY-3 PERCENT (g)	2.3%	6.5%	0%	0%
TERMINAL (d)	1/35 (3%)	2/40 (5%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	729 (T)	681	---	---
HC TUMORS SAME RTE	2/50 (4%)			
HC TUMORS ALL RTES	16/1249 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.176N	P=0.321	P=0.495N	P=0.492N
POLY 1.5	P=0.179N	P=0.316	P=0.498N	P=0.496N
POLY 6	P=0.172N	P=0.329	P=0.492N	P=0.487N
COCH-ARM / FISHERS	P=0.185N	P=0.309	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.132N	P=0.171	P=0.158N	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)



TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Ovary  
 Cystadenoma**

**TUMOR RATES**

OVERALL (a)	4/49 (8%)	3/50 (6%)	2/49 (4%)	2/48 (4%)
POLY-3 RATE (b)	4/42.96	3/45.74	2/44.23	2/44.48
POLY-3 PERCENT (g)	9.3%	6.6%	4.5%	4.5%
TERMINAL (d)	4/34 (12%)	3/40 (8%)	1/39 (3%)	2/39 (5%)
FIRST INCIDENCE	729 (T)	729 (T)	659	729 (T)
HC TUMORS SAME RTE	2/47 (4%)			
HC TUMORS ALL RTES	46/1221 (4%)			

**STATISTICAL TESTS**

POLY 3	P=0.355N	P=0.466N	P=0.323N	P=0.321N
POLY 1.5	P=0.362N	P=0.474N	P=0.331N	P=0.333N
POLY 6	P=0.346N	P=0.455N	P=0.313N	P=0.306N
COCH-ARM / FISHERS	P=0.368N	P=0.489N	P=0.339N	P=0.349N
MAX-ISO-POLY-3	P=0.300N	P=0.321N	P=0.193N	P=0.193N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Pituitary Gland: Pars Distalis or Unspecified Site  
 Adenoma**

**TUMOR RATES**

OVERALL (a)	1/49 (2%)	2/47 (4%)	4/50 (8%)	4/50 (8%)
POLY-3 RATE (b)	1/43.38	2/43.71	4/44.97	4/45.74
POLY-3 PERCENT (g)	2.3%	4.6%	8.9%	8.8%
TERMINAL (d)	0/35 (0%)	2/39 (5%)	4/40 (10%)	4/40 (10%)
FIRST INCIDENCE	659	729 (T)	729 (T)	729 (T)
HC TUMORS SAME RTE	1/46 (2%)			
HC TUMORS ALL RTES	97/1216 (8%)			

**STATISTICAL TESTS**

POLY 3	P=0.228	P=0.503	P=0.189	P=0.195
POLY 1.5	P=0.224	P=0.497	P=0.187	P=0.190
POLY 6	P=0.234	P=0.510	P=0.192	P=0.201
COCH-ARM / FISHERS	P=0.222	P=0.484	P=0.187	P=0.187
MAX-ISO-POLY-3	P=0.178	P=0.286	P=0.093	P=0.098
HISTCONT SAME RTE	P=0.251	P=0.233	P=0.157	P=0.164
HISTCONT ALL RTES	P=0.204	P=0.356	P=0.106	P=0.113

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
<b>Skeletal Muscle Sarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/43.96	0/45.74	2/44.97	0/45.74
POLY-3 PERCENT (g)	0%	0%	4.5%	0%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	2/40 (5%)	0/40 (0%)
FIRST INCIDENCE	---	---	729 (T)	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	3/1249 (0%)			

**STATISTICAL TESTS**

POLY 3	P=0.618N	(e)	P=0.242	(e)
POLY 1.5	P=0.622N	(e)	P=0.240	(e)
POLY 6	P=0.612N	(e)	P=0.246	(e)
COCH-ARM / FISHERS	P=0.624N	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.270	(e)	P=0.081	(e)
HISTCONT SAME RTE	(h)	(e)	(h)	(e)
HISTCONT ALL RTES	(h)	(e)	(h)	(e)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Skin  
 Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, or Fibrous Histiocytoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	5/50 (10%)	1/50 (2%)	3/50 (6%)	2/50 (4%)
POLY-3 RATE (b)	5/44.83	1/45.74	3/45.53	2/45.74
POLY-3 PERCENT (g)	11.2%	2.2%	6.6%	4.4%
TERMINAL (d)	1/35 (3%)	1/40 (3%)	1/40 (3%)	2/40 (5%)
FIRST INCIDENCE	659	729 (T)	646	729 (T)
HC TUMORS SAME RTE	3/50 (6%)			
HC TUMORS ALL RTES	53/1249 (4%)			

**STATISTICAL TESTS**

POLY 3	P=0.387N	P=0.097N	P=0.348N	P=0.208N
POLY 1.5	P=0.390N	P=0.098N	P=0.352N	P=0.212N
POLY 6	P=0.383N	P=0.096N	P=0.342N	P=0.203N
COCH-ARM / FISHERS	P=0.389N	P=0.102N	P=0.357N	P=0.218N
MAX-ISO-POLY-3	P=0.150N	P=0.043N*	P=0.226N	P=0.116N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
<b>Skin</b>				
<b>Fibrosarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	3/50 (6%)	0/50 (0%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	3/44.66	0/45.74	2/45.27	1/45.74
POLY-3 PERCENT (g)	6.7%	0%	4.4%	2.2%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	1/40 (3%)	1/40 (3%)
FIRST INCIDENCE	659	---	646	729 (T)
HC TUMORS SAME RTE	3/50 (6%)			
HC TUMORS ALL RTES	20/1249 (2%)			

**STATISTICAL TESTS**

POLY 3	P=0.475N	P=0.114N	P=0.494N	P=0.297N
POLY 1.5	P=0.477N	P=0.116N	P=0.497N	P=0.301N
POLY 6	P=0.472N	P=0.113N	P=0.490N	P=0.292N
COCH-ARM / FISHERS	P=0.476N	P=0.121N	P=0.500N	P=0.309N
MAX-ISO-POLY-3	P=0.194N	P=0.038N*	P=0.319N	P=0.151N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Skin  
 Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	5/50 (10%)	1/50 (2%)	3/50 (6%)	2/50 (4%)
POLY-3 RATE (b)	5/44.83	1/45.74	3/45.53	2/45.74
POLY-3 PERCENT (g)	11.2%	2.2%	6.6%	4.4%
TERMINAL (d)	1/35 (3%)	1/40 (3%)	1/40 (3%)	2/40 (5%)
FIRST INCIDENCE	659	729 (T)	646	729 (T)
HC TUMORS SAME RTE	3/50 (6%)			
HC TUMORS ALL RTES	53/1249 (4%)			

**STATISTICAL TESTS**

POLY 3	P=0.387N	P=0.097N	P=0.348N	P=0.208N
POLY 1.5	P=0.390N	P=0.098N	P=0.352N	P=0.212N
POLY 6	P=0.383N	P=0.096N	P=0.342N	P=0.203N
COCH-ARM / FISHERS	P=0.389N	P=0.102N	P=0.357N	P=0.218N
MAX-ISO-POLY-3	P=0.150N	P=0.043N*	P=0.226N	P=0.116N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
<b>Skin</b>				
<b>Hemangiosarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/43.96	0/45.74	1/45.63	0/45.74
POLY-3 PERCENT (g)	2.3%	0%	2.2%	0%
TERMINAL (d)	1/35 (3%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	729 (T)	---	508	---
HC TUMORS SAME RTE	1/50 (2%)			
HC TUMORS ALL RTES	17/1249 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.486N	P=0.492N	P=0.752N	P=0.492N
POLY 1.5	P=0.487N	P=0.495N	P=0.756N	P=0.496N
POLY 6	P=0.484N	P=0.488N	P=0.747N	P=0.487N
COCH-ARM / FISHERS	P=0.486N	P=0.500N	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.261N	P=0.158N	P=0.489N	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
<b>Skin</b>				
<b>Liposarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.96	2/46.49	0/44.97	0/45.74
POLY-3 PERCENT (g)	0%	4.3%	0%	0%
TERMINAL (d)	0/35 (0%)	1/40 (3%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	---	456	---	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	1/1249 (0%)			

**STATISTICAL TESTS**

POLY 3	P=0.389N	P=0.250	(e)	(e)
POLY 1.5	P=0.394N	P=0.246	(e)	(e)
POLY 6	P=0.382N	P=0.255	(e)	(e)
COCH-ARM / FISHERS	P=0.403N	P=0.247	(e)	(e)
MAX-ISO-POLY-3	P=0.269N	P=0.088	(e)	(e)
HISTCONT SAME RTE	(h)	(h)	(e)	(e)
HISTCONT ALL RTES	(h)	(h)	(e)	(e)



TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Spleen  
 Hemangiosarcoma**

**TUMOR RATES**

OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/43.96	1/46.12	0/44.97	1/46.55
POLY-3 PERCENT (g)	0%	2.2%	0%	2.2%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	---	622	---	420
HC TUMORS SAME RTE	0/47 (0%)			
HC TUMORS ALL RTES	24/1230 (2%)			

**STATISTICAL TESTS**

POLY 3	P=0.500	P=0.510	(e)	P=0.511
POLY 1.5	P=0.494	P=0.506	(e)	P=0.506
POLY 6	P=0.507	P=0.514	(e)	P=0.518
COCH-ARM / FISHERS	P=0.486	P=0.500	(e)	P=0.500
MAX-ISO-POLY-3	P=0.284	P=0.171	(e)	P=0.173
HISTCONT SAME RTE	P=0.286	P=0.221	(e)	P=0.223
HISTCONT ALL RTES	P=0.328	P=0.203	(e)	P=0.206

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Stomach, Forestomach  
 Squamous Cell Carcinoma or Papilloma Squamous**

TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/43.96	0/45.74	1/44.97	0/45.74
POLY-3 PERCENT (g)	2.3%	0%	2.2%	0%
TERMINAL (d)	1/35 (3%)	0/40 (0%)	1/40 (3%)	0/40 (0%)
FIRST INCIDENCE	729 (T)	---	729 (T)	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	22/1249 (2%)			

**STATISTICAL TESTS**

POLY 3	P=0.485N	P=0.492N	P=0.756N	P=0.492N
POLY 1.5	P=0.487N	P=0.495N	P=0.758N	P=0.496N
POLY 6	P=0.484N	P=0.488N	P=0.752N	P=0.487N
COCH-ARM / FISHERS	P=0.486N	P=0.500N	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.261N	P=0.158N	P=0.493N	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Stomach, Forestomach  
 Squamous Cell Papilloma**

TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/43.96	0/45.74	1/44.97	0/45.74
POLY-3 PERCENT (g)	2.3%	0%	2.2%	0%
TERMINAL (d)	1/35 (3%)	0/40 (0%)	1/40 (3%)	0/40 (0%)
FIRST INCIDENCE	729 (T)	---	729 (T)	---
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	20/1249 (2%)			

**STATISTICAL TESTS**

POLY 3	P=0.485N	P=0.492N	P=0.756N	P=0.492N
POLY 1.5	P=0.487N	P=0.495N	P=0.758N	P=0.496N
POLY 6	P=0.484N	P=0.488N	P=0.752N	P=0.487N
COCH-ARM / FISHERS	P=0.486N	P=0.500N	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.261N	P=0.158N	P=0.493N	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**Thyroid Gland: Follicular Cell  
 Carcinoma or Adenoma**

**TUMOR RATES**

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/48 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/43.96	0/45.74	0/43.27	0/45.74
POLY-3 PERCENT (g)	4.6%	0%	0%	0%
TERMINAL (d)	2/35 (6%)	0/40 (0%)	0/39 (0%)	0/40 (0%)
FIRST INCIDENCE	729 (T)	---	---	---
HC TUMORS SAME RTE	1/46 (2%)			
HC TUMORS ALL RTES	32/1234 (3%)			

**STATISTICAL TESTS**

POLY 3	P=0.354N	P=0.228N	P=0.241N	P=0.228N
POLY 1.5	P=0.352N	P=0.231N	P=0.244N	P=0.233N
POLY 6	P=0.356N	P=0.224N	P=0.236N	P=0.222N
COCH-ARM / FISHERS	P=0.349N	P=0.247N	P=0.258N	P=0.247N
MAX-ISO-POLY-3	P=0.037N*	P=0.076N	P=0.078N	P=0.076N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
<b>Uterus</b>				
<b>Polyp Stromal</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	2/50 (4%)	1/50 (2%)	0/50 (0%)	4/50 (8%)
POLY-3 RATE (b)	2/44.73	1/45.74	0/44.97	4/45.74
POLY-3 PERCENT (g)	4.5%	2.2%	0%	8.8%
TERMINAL (d)	1/35 (3%)	1/40 (3%)	0/40 (0%)	4/40 (10%)
FIRST INCIDENCE	443	729 (T)	---	729 (T)
HC TUMORS SAME RTE	0/50 (0%)			
HC TUMORS ALL RTES	33/1249 (3%)			

**STATISTICAL TESTS**

POLY 3	P=0.082	P=0.492N	P=0.236N	P=0.347
POLY 1.5	P=0.081	P=0.495N	P=0.237N	P=0.341
POLY 6	P=0.084	P=0.488N	P=0.233N	P=0.358
COCH-ARM / FISHERS	P=0.081	P=0.500N	P=0.247N	P=0.339
MAX-ISO-POLY-3	P=0.091	P=0.276N	P=0.076N	P=0.211
HISTCONT SAME RTE	P=0.126	P=0.421	(e)	P=0.135
HISTCONT ALL RTES	P=0.104	P=1.000	(e)	P=0.088

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
<b>All Organs</b>				
<b>Hemangioma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	1/50 (2%)	1/50 (2%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	1/44.17	1/45.93	0/44.97	2/45.74
POLY-3 PERCENT (g)	2.3%	2.2%	0%	4.4%
TERMINAL (d)	0/35 (0%)	0/40 (0%)	0/40 (0%)	2/40 (5%)
FIRST INCIDENCE	672	680	---	729 (T)
HC TUMORS SAME RTE	1/50 (2%)			
HC TUMORS ALL RTES	20/1249 (2%)			

**STATISTICAL TESTS**

POLY 3	P=0.314	P=0.752N	P=0.496N	P=0.512
POLY 1.5	P=0.311	P=0.755N	P=0.498N	P=0.506
POLY 6	P=0.318	P=0.748N	P=0.494N	P=0.520
COCH-ARM / FISHERS	P=0.309	P=0.753N	P=0.500N	P=0.500
MAX-ISO-POLY-3	P=0.299	P=0.488N	P=0.158N	P=0.294
HISTCONT SAME RTE	P=0.242	P=1.000	(e)	P=0.205
HISTCONT ALL RTES	P=0.316	P=0.556	(e)	P=0.210

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
<b>All Organs</b>				
<b>Hemangiosarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	3/50 (6%)	2/50 (4%)
POLY-3 RATE (b)	1/43.96	2/46.12	3/45.63	2/46.55
POLY-3 PERCENT (g)	2.3%	4.3%	6.6%	4.3%
TERMINAL (d)	1/35 (3%)	1/40 (3%)	2/40 (5%)	1/40 (3%)
FIRST INCIDENCE	729 (T)	622	508	420
HC TUMORS SAME RTE	3/50 (6%)			
HC TUMORS ALL RTES	60/1249 (5%)			

**STATISTICAL TESTS**

POLY 3	P=0.591	P=0.517	P=0.319	P=0.520
POLY 1.5	P=0.581	P=0.511	P=0.313	P=0.511
POLY 6	P=0.603	P=0.525	P=0.327	P=0.531
COCH-ARM / FISHERS	P=0.571	P=0.500	P=0.309	P=0.500
MAX-ISO-POLY-3	P=0.393	P=0.299	P=0.168	P=0.302
HISTCONT SAME RTE	P=0.538	P=0.443	P=0.269	P=0.448
HISTCONT ALL RTES	P=0.457	P=0.374	P=0.200	P=0.379

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**All Organs  
 Hemangiosarcoma or Hemangioma**

TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	3/50 (6%)	3/50 (6%)	4/50 (8%)
POLY-3 RATE (b)	2/44.17	3/46.31	3/45.63	4/46.55
POLY-3 PERCENT (g)	4.5%	6.5%	6.6%	8.6%
TERMINAL (d)	1/35 (3%)	1/40 (3%)	2/40 (5%)	3/40 (8%)
FIRST INCIDENCE	672	622	508	420
HC TUMORS SAME RTE	4/50 (8%)			
HC TUMORS ALL RTES	79/1249 (6%)			

**STATISTICAL TESTS**

POLY 3	P=0.349	P=0.521	P=0.515	P=0.362
POLY 1.5	P=0.340	P=0.514	P=0.508	P=0.351
POLY 6	P=0.358	P=0.532	P=0.523	P=0.374
COCH-ARM / FISHERS	P=0.330	P=0.500	P=0.500	P=0.339
MAX-ISO-POLY-3	P=0.369	P=0.346	P=0.339	P=0.226
HISTCONT SAME RTE	P=0.510	P=0.502	P=0.493	P=0.349
HISTCONT ALL RTES	P=0.429	P=0.437	P=0.427	P=0.276



TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
<b>All Organs</b>				
<b>Histiocytic Sarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	2/50 (4%)	4/50 (8%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	2/44.17	4/47.78	0/44.97	1/46.02
POLY-3 PERCENT (g)	4.5%	8.4%	0%	2.2%
TERMINAL (d)	1/35 (3%)	1/40 (3%)	0/40 (0%)	0/40 (0%)
FIRST INCIDENCE	672	446	---	654
HC TUMORS SAME RTE	2/50 (4%)			
HC TUMORS ALL RTES	31/1249 (3%)			

**STATISTICAL TESTS**

POLY 3	P=0.270N	P=0.374	P=0.233N	P=0.486N
POLY 1.5	P=0.275N	P=0.361	P=0.235N	P=0.493N
POLY 6	P=0.263N	P=0.388	P=0.230N	P=0.476N
COCH-ARM / FISHERS	P=0.281N	P=0.339	P=0.247N	P=0.500N
MAX-ISO-POLY-3	P=0.157N	P=0.239	P=0.076N	P=0.272N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**All Organs  
 Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or Undifferentiated Cell Type**

TUMOR RATES	#	#	#	#
OVERALL (a)	14/50 (28%)	15/50 (30%)	11/50 (22%)	2/50 (4%)
POLY-3 RATE (b)	14/44.73	15/46.11	11/45.18	2/45.74
POLY-3 PERCENT (g)	31.3%	32.5%	24.4%	4.4%
TERMINAL (d)	11/35 (31%)	13/40 (33%)	10/40 (25%)	2/40 (5%)
FIRST INCIDENCE	547	680	672	729 (T)
HC TUMORS SAME RTE	6/50 (12%)			
HC TUMORS ALL RTES	284/1249 (23%)			

**STATISTICAL TESTS**

POLY 3	P<0.001N**	P=0.540	P=0.308N	P<0.001N**
POLY 1.5	P<0.001N**	P=0.527	P=0.316N	P<0.001N**
POLY 6	P<0.001N**	P=0.560	P=0.296N	P<0.001N**
COCH-ARM / FISHERS	P<0.001N**	P=0.500	P=0.322N	P<0.001N**
MAX-ISO-POLY-3	P<0.001N**	P=0.449	P=0.232N	P<0.001N**
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**All Organs  
 Benign Tumors**

**TUMOR RATES**

	#	#	#	#
OVERALL (a)	27/50 (54%)	27/50 (54%)	31/50 (62%)	32/50 (64%)
POLY-3 RATE (b)	27/45.59	27/46.82	31/47.01	32/46.1
POLY-3 PERCENT (g)	59.2%	57.7%	66%	69.4%
TERMINAL (d)	23/35 (66%)	22/40 (55%)	27/40 (68%)	30/40 (75%)
FIRST INCIDENCE	443	622	508	654
HC TUMORS SAME RTE	25/50 (50%)			
HC TUMORS ALL RTEs	644/1249 (52%)			

**STATISTICAL TESTS**

POLY 3	P=0.151	P=0.524N	P=0.322	P=0.206
POLY 1.5	P=0.153	P=0.544N	P=0.294	P=0.198
POLY 6	P=0.153	P=0.483N	P=0.362	P=0.226
COCH-ARM / FISHERS	P=0.178	P=0.579N	P=0.272	P=0.208
MAX-ISO-POLY-3	P=0.225	P=0.438N	P=0.252	P=0.149
HISTCONT SAME RTE	P=0.106	P=0.287	P=0.130	P=0.134
HISTCONT ALL RTEs	P=0.261	P=0.577	P=0.309	P=0.176

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG
<b>All Organs</b>				
<b>Malignant Tumors</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	27/50 (54%)	36/50 (72%)	31/50 (62%)	25/50 (50%)
POLY-3 RATE (b)	27/46.77	36/49.61	31/48.53	25/47.7
POLY-3 PERCENT (g)	57.7%	72.6%	63.9%	52.4%
TERMINAL (d)	17/35 (49%)	27/40 (68%)	23/40 (58%)	20/40 (50%)
FIRST INCIDENCE	547	446	442	420
HC TUMORS SAME RTE	26/50 (52%)			
HC TUMORS ALL RTEs	629/1249 (50%)			

**STATISTICAL TESTS**

POLY 3	P=0.085N	P=0.091	P=0.342	P=0.377N
POLY 1.5	P=0.084N	P=0.076	P=0.312	P=0.392N
POLY 6	P=0.090N	P=0.106	P=0.372	P=0.373N
COCH-ARM / FISHERS	P=0.086N	P=0.048*	P=0.272	P=0.421N
MAX-ISO-POLY-3	P=0.140N	P=0.066	P=0.273	P=0.303N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTEs	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
 Androstenedione  
 CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
 Time Report Requested: 12:55:58  
 First Dose M/F: 12/16/02 / 12/16/02  
 Lab: SRI

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
 TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	0 MG/KG	2 MG/KG	10 MG/KG	50 MG/KG

**All Organs  
 Malignant and Benign Tumors**

TUMOR RATES	#	#	#	#
OVERALL (a)	40/50 (80%)	43/50 (86%)	43/50 (86%)	38/50 (76%)
POLY-3 RATE (b)	40/47.93	43/49.61	43/49.01	38/47.7
POLY-3 PERCENT (g)	83.5%	86.7%	87.7%	79.7%
TERMINAL (d)	28/35 (80%)	34/40 (85%)	34/40 (85%)	33/40 (83%)
FIRST INCIDENCE	443	446	442	420
HC TUMORS SAME RTE	39/50 (78%)			
HC TUMORS ALL RTEs	939/1249 (75%)			

**STATISTICAL TESTS**

POLY 3	P=0.227N	P=0.435	P=0.377	P=0.413N
POLY 1.5	P=0.204N	P=0.400	P=0.336	P=0.406N
POLY 6	P=0.272N	P=0.457	P=0.420	P=0.444N
COCH-ARM / FISHERS	P=0.168N	P=0.298	P=0.298	P=0.405N
MAX-ISO-POLY-3	P=0.322N	P=0.328	P=0.275	P=0.313N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTEs	(h)	(h)	(h)	(h)

TDMS No. 99024 - 08  
Test Type: CHRONIC  
Route: GAVAGE  
Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS  
Androstenedione  
CAS Number: 63-05-8

Date Report Requested: 05/09/2008  
Time Report Requested: 12:55:58  
First Dose M/F: 12/16/02 / 12/16/02  
Lab: SRI

## LEGEND

- (a) Number of tumor-bearing animals/number of animals examined at site.
  - (b) Number of tumor-bearing animals/Poly-3 number
  - (d) Observed incidence at terminal kill.
  - (e) Value of Statistic cannot be computed.
  - (f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group.
  - (g) Poly-3 adjusted lifetime tumor incidence.
  - (h) Value of Historical Controls statistic is only calculated when Poly-3 trend is positive and when there is more than one tumor in the treatment groups.
  - (I) Interim sacrifice
  - (T) Terminal sacrifice
  - # Tumor rates based on numbers of animals necropsied.
  - \* To the right of any statistical result, indicates significance at ( $P \leq 0.05$ ).
  - \*\* To the right of any statistical result, indicates significance at ( $P \leq 0.01$ ).
  - N Indicates a negative trend for all tests
- The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

\*\*\* END OF REPORT \*\*\*